Sonata Software, a global strategic IT services firm announced today that it has signed a definitive agreement to acquire through its US subsidiary, a 100% stake in the enterprise mobility enablement technology provider Halosys. Based in Santa Clara, California, Halosys is an innovator in providing technology platform and solutions that help enterprises realize the transformational impact of mobile on business. Halosys provides a single Unified Enterprise Mobile Enablement platform that enables businesses build, secure, manage and deploy an enterprise wide mobile applications portfolio. This is achieved by building critical features of multiple hitherto discrete mobility systems such as mBaaS (Mobile Back-end-as-a-Service), MADP (Mobile Application Development Platform), MAM (Mobile Application Management) and API (Application Programming Interface) in a unified platform with consistent workflows and enhanced user interfaces. The platform seamlessly extends existing enterprise security, identity and business applications to the mobile applications. This simplifies, accelerates and ensures a reliable way to execute mobility programs at scale, with an underlying architecture that adheres to emerging mobile & IoT technology trends. Sonata serves world leaders in ISV, Travel, Retail and Consumer goods businesses with digital business readiness solutions and sees the Halosys acquisition as a key piece in providing an end to end mobile solutions to customers.
To view the multimedia news release, go to http://www.multivu.com/players/English/7591351-sonata-invests-acquires-halosys/
Connections between Silicon Valley technology companies and China technology leaders are allowing for rapid growth and expansion on both sides of the Pacific. GMIC Silicon Valley will welcome executives from over 60 countries for one of the only US conferences that highlights the impact of Asia on the rapidly changing mobile industry.
At GMIC, attendees will hear from the mobile leaders who are leading this change. Visionary leaders like Sheng Fu (CEO, Cheetah Mobile), Manish Chandra (Founder & CEO, Poshmark), Max Ventilla (Founder & CEO, AltSchool), and Jenny Lee (Managing Partner, GGV Capital) will cover the trends driving today’s mobile industry and highlight the ways that companies will continue to build for the future of mobile technology.
To view the multimedia release go to:
http://www.multivu.com/players/English/7539731-global-mobile-internet-conference/
The Leukemia & Lymphoma Society (LLS), the world’s leading voluntary non-profit dedicated to blood cancers, released 30 “proof points” - one for each day of September, Blood Cancer Awareness Month - to demonstrate its impact on the cancer landscape and progress towards a world without blood cancers.
LLS has invested more than $1 billion in research to advance breakthrough therapies and cures for blood cancer patients. In many cases, those treatments are now helping patients with other cancers and chronic diseases. Due to its focus on blood cancers, survival rates are improving. Since the early 1960s, five-year survival rates for many blood cancer patients have doubled, tripled and even quadrupled.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554851-lls-blood-cancer-awareness-month/
Lake Research Partners and Bellwether Research and Consulting recently released a new national poll sponsored by the American Motorcyclist Association (AMA) that finds likely 2016 voters have widespread and serious concerns about ethanol’s unintended consequences—including damage to engines, land conversion and food prices.
“Voters across party lines express grave concerns for the impacts of the corn ethanol mandate from the Renewable Fuel Standard that touch many parts of their lives from the cars they drive to the food they buy,” said Celinda Lake, president of Lake Research Partners. “They strongly support bi-partisan proposals that would reduce the impact of corn ethanol, and particularly support the Environmental Protection Agency reducing the amount of corn ethanol required by law.”
As the EPA recently closed the comment period on its proposed ethanol volumes for 2014, 2015 and 2016, the poll also shows that 67 percent of people favor the agency setting ethanol volumes below what is required by law, with 68 percent of Democrats and 71 percent of Republicans supporting volumes lower than the statute.
To view the multimedia release go to: http://www.multivu.com/players/English/7576751-ama-national-ethanol-voter-poll/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
The Light of Life Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Inc., and Eisai Inc. today announced the launch of Myths and Truths About Thyroid Cancer, an interactive, educational campaign designed to help dispel the myth that thyroid cancer is a “good cancer.” Because most thyroid cancers can be successfully treated, many are told if you are going to get cancer, thyroid cancer is the one to have, which has led to this misperception. However, whether successfully treated or not, the truth is all cancers can have a significant impact on a person’s life, beginning with the shock and distress of hearing the word “cancer” at diagnosis. In honor of Thyroid Cancer Awareness Month and the tens of thousands who receive a thyroid cancer diagnosis each year, Myths and Truths About Thyroid Cancer illustrates the life-changing realities of this disease.
“As a thyroid cancer survivor, I urge people to stop referring to thyroid cancer as the ‘good cancer,’ as I believe it downplays patients’ experiences,” said Joan Shey, founder of the Light of Life Foundation. “I hear time and time again from patients how difficult their diagnosis and treatment were and that their scars are more than skin deep. My hope is that this campaign can educate about the many types of thyroid cancer and change the thyroid cancer conversation.”
“Being part of a community of survivors is very important for people coping with thyroid cancer,” said Gary Bloom, thyroid cancer survivor and co-founder and executive director of ThyCa: Thyroid Cancer Survivors’ Association. “ThyCa takes this to heart, which is why we are proud to provide support and resources to the thyroid cancer community. We also know more needs to be done to elevate awareness of thyroid cancer and what patients need in terms of support for the rest of our lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7595951-eisai-thyroid-cancer-myths/
Do you want to live a kingdom driven life? Do you want to discover your divine purpose? Do you want to discover the life you were born to live and ignite it with passion?
The kingdom driven life by Pastor Sunday Adelaja is a book that will help you to do just that. You may have been battling with questions like, what on earth am I here for?
What is the purpose of life? Matthew 6:33, Jesus instructs us to seek first the Kingdom. Seeking the kingdom of God should be our priority.
If we are going to make a significant impact on the earth, possess and disciple nations; we need to understand the precepts and principles of the kingdom.
Pastor Sunday Adelaja’s book will help you discover God’s priority for mankind, your original purpose for existence, and the source of meaning behind life.
You will be equipped with the tools, and strategies for promoting and expanding the Kingdom.
Many admit that this book is one of the top 3 books written in the last 1000 years.
To get your own copy, click here: http://this-productrocks.com/KingdomDrivenLife
Tags:
the kingdom driven life, kingdom driven life, purpose driven life, purpose of life, the purpose driven life, the purpose of life, purpose in life, what is the purpose of life, keys to the kingdom, seek first the kingdom of god, kingdom of god, evangelism, spiritual awakening, spiritual disciplines, personal growth, holy spirit, the holy spirit, spiritual gifts, word of faith, word of god, christian, christian books, spirituality, gospel, jesus, church, christianity, bible study, god, bible verses, prayer, prayers, daily devotions, discipleship, what is the kingdom of god, church leaders, spiritual leadership, church growth, kindle, kindle books, kindle book
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
If there’s one thing that socially responsible businesses have learned, it’s that they can’t go at it alone. Whether it’s implementing responsible sourcing initiatives or creating a positive corporate model to make an impact on sustainability, there is strength in numbers. So where did Ben & Jerry’s turn for help and inspiration for its latest ice cream flavor? Colorado-based New Belgium Brewing. Never has the phrase “polishing off a pint” been so perfectly poised in any partnership for a delicious double-entendre.
Collectively committed to making a better impact in their global communities, the two B Corp companies proudly introduced Salted Caramel Brown-ie Ale ice cream, which will be featured in Ben & Jerry’s Scoop Shops as well as in pints across the country as a Limited Batch flavor this fall (MSRP $4.89). The concoction consists of New Belgium Brown Ale Ice Cream with Salted Caramel Swirls and Fudge Brownies. The ice cream, arriving on shelves this month, was unveiled Wednesday evening at a Washington D.C. launch “Brew-Ha-Ha” in the confines of the historic Howard Theatre. The launch event was heralded as “a night of music, climate activism, beer, and ice cream.” Musicians Galactic and Dr. Dog performed at the unveiling of Ben & Jerry’s newest ice cream flavor to highlight climate activism.
To view the multimedia release go to:
http://www.multivu.com/players/English/7648451-ben-and-jerry-s-new-belgium-brewery/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
